Phil Nadeau

Stock Analyst at TD Cowen

(2.81)
# 1,950
Out of 5,090 analysts
23
Total ratings
50%
Success rate
36.12%
Average return

Stocks Rated by Phil Nadeau

Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $50$45
Current: $23.85
Upside: +88.68%
Kura Oncology
Nov 21, 2024
Reiterates: Buy
Price Target: n/a
Current: $11.75
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55$65
Current: $105.72
Upside: -38.52%
Biogen
Oct 31, 2024
Maintains: Buy
Price Target: $300$275
Current: $182.74
Upside: +50.49%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125$120
Current: $53.14
Upside: +125.82%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450$500
Current: $456.61
Upside: +9.50%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $21.24
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $14.96
Upside: -
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.48
Upside: -
Annexon
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $4.71
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $6.23
Upside: -